Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
about
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groupsStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.
P2860
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@en
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@nl
type
label
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@en
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@nl
prefLabel
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@en
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@nl
P2093
P1433
P1476
Preclinical antitumour activit ...... vel tubulin-interacting agent.
@en
P2093
D P Berger
G Schwartsmann
H C Dreef-van der Meulen
H H Fiebig
H M Pinedo
H R Hendriks
R E Henrar
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A058334
P577
1992-11-01T00:00:00Z